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Abstract
Background: The Nuclear Receptor 2F2 (NR2F2/COUP-TFII) heterozygous knockout mice display low basal insulinemia and
enhanced insulin sensitivity. We previously established that insulin represses NR2F2 gene expression in pancreatic b-cells.
The cis-regulatory region of the NR2F2 promoter is unknown and its influence on metabolism in humans is poorly
understood. The present study aimed to identify the regulatory regions that control NR2F2 gene transcription and to
evaluate the effect of NR2F2 promoter variation on glucose homeostasis in humans.
Methodology/Principal Findings: RegulationoftheNR2F2promoterwasassessedusinggenereporterassays,ChIPandgelshift
experiments. The effects of variation at SNP rs3743462 inNR2F2 on quantitativemetabolic traits were studied in two European
prospective cohorts. We identified a minimal promoter region that down-regulates NR2F2 expression by attenuating HNF4a
activation inresponsetohighglucoseconcentrations.SubjectsoftheFrenchDESIRpopulation,whocarriedthers3743462T-to-C
polymorphism, located in thedistalglucose-responsivepromoter, displayed lowerbasal insulin levelsand lowerHOMA-IR index.
The C-allele at rs3743462 was associated with increased NR2F2 binding and decreased NR2F2 gene expression.
Conclusions/Significance: The rs3743462 polymorphism affects glucose-responsive NR2F2 promoter regulation and thereby
may influence whole-body insulin sensitivity, suggesting a role of NR2F2 in the control of glucose homeostasis in humans.
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Introduction
NR2F2 is a nuclear receptor also known as the chicken
ovalbumin upstream promoter transcription factor II (COUP-
TFII). It exerts complex pleiotropic effects on glucose and lipid
metabolism in various tissues and at different periods of life
[1,2,3,4,5]. Li et al. observed that NR2F2 heterozygous knockout
mice displayed lower basal insulinemia and enhanced insulin
sensitivity compared to wild type mice [4]. These observations
suggest that variations in NR2F2 gene expression might play an
important metabolic function in rodents. Furthermore, we
established that NR2F2 gene expression is modulated by nutri-
tional status in pancreatic b-cells [3], hepatocytes [3] and
ventromedial hypothalamic neurons [6]. We also described, in
pancreatic b-cells, a cross-regulation between NR2F2 and the
transcription factor hepatocyte nuclear factor-4a (HNF4a), in-
volved in the regulation of insulin secretion [7,3]. These data
further support a role for insulin and glucose in the control of
NR2F2 and a pivotal role for this transcription factor in the
control of glucose homeostasis in vivo.
The precise function of NR2F2 in the control of glucose
homeostasis in humans is poorly understood. We recently
established the presence of NR2F2 expression in human pancreatic
b-cells [5]. To our knowledge, no specific mutations in NR2F2
have been identified in relation to diabetes phenotypes and
variations in the human NR2F2 sequence have not previously been
associated with changes in glucose metabolism in human
populations. Such observations may provide further support for
a role for NR2F2 in the glucose-insulin metabolism in humans.
The present report aimed to identify and characterize some of
the cis-regulatory regions of the NR2F2 promoter that confer
glucose responsiveness in vitro and in vivo. We used the glucose
sensitive INS-1 832/13 pancreatic b-cell line to study the influence
of high glucose concentrations on NR2F2 responsiveness. We
investigated the association between single nucleotide polymorph-
isms (SNPs) in the promoter region of NR2F2 and quantitative
traits related to glucose homeostasis in the French prospective
DESIR cohort and followed-up the lead SNP, rs3743462, in the
European birth cohorts NFBC-1966 and NFBC-1986. Finally, we
used fusion gene and gel shift assays to characterize the
consequences of the allelic change at rs3743462 on NR2F2
promoter activity.
Results
High Glucose Concentrations in vitro Promote
Repression of the Proximal Region of NR2F2 by
Attenuation of the Activation Effect of HNF4a
To map the cis-regulatory elements responsible for glucose
responsiveness in NR2F2, we transiently co-transfected luciferase
plasmid reporters in a INS-1 832/13 b-cell line with various
deleted sections of the NR2F2 regulatory region. This corresponds
to a fragment of 4 kbp that encompasses the upstream NR2F2
regulatory region that was shown to be sufficient to direct NR2F2
expression in pancreatic b-cells [8]. In comparison with a concen-
tration of 5 mM, a glucose concentration of 20 mM provoked
a 45% reduction of luciferase activity (P,0.05) in INS-1 832/13 b-
cells co-transfected with the full length NR2F2 promoter construct
23210/+873) (Fig. 1A). These measured impacts were consistent
with previous observations on endogenous reduction of NR2F2
mRNA abundance by high glucose concentrations (Fig. 1B and
[3]). The deletion analysis further established that the fragment
from 2328 to +873 was the minimal region required to confer
a significant inhibition by high glucose concentrations (Fig. 1A). In
this proximal promoter, we previously showed that HNF4a binds
the conserved direct repeat-1 (DR-1) hormone response element
(HRE) [7]. We also showed that HNF4a is able to activate the
endogenous NR2F2 gene in INS-1 832/13 b-cells [7]. As shown in
figure 1B, we observed the same reduction of HNF4a mRNA
levels as observed for NR2F2 mRNA levels in the presence of high
glucose levels in INS-1 cells suggesting that this transcription factor
could be involved in the glucose responsiveness of NR2F2. As show
in figure 1C, the antibodies for HNF4a immunoprecipitated with
the promoter region of NR2F2, revealing the presence of
endogenous HNF4a on this DNA binding site. A high glucose
concentration (20 mM) in comparison to a concentration of 5 mM
induced a significant reduction of immunoprecipitation with anti-
HNF4a antibodies. HNF4a bound to the DR-1 DNA binding site
in a glucose-dependent manner. In COS-7 cells, that lack
endogenous expression of HNF4a, the co-transfection with an
HNF4a expression vector and the 2328/+873 luciferase reporter
plasmid induced a 4-fold increase in luciferase activity (Fig. 1D).
Moreover, when the DR-1 DNA binding site was mutated in the
2328/+873 construct, we measured a 70% reduction in luciferase
activity (Fig. 1E). This suggests that a nuclear receptor is
a transactivator of the NR2F2 promoter in b-cells cultured in
5 mM glucose, a condition that allows maximal expression of
NR2F2. Furthermore the mutations at the DR-1 binding site led
to a significantly weaker repression by 20 mM glucose (Fig. 1E).
Altogether these results suggest that HNF4a is a transcription
factor required for inhibition of NR2F2 promoter activity by high
concentrations of glucose. They also suggest a more complex
pattern of regulation with additional factors involved in the
inhibition of NR2F2 transcription activity by high concentrations
of glucose.
Genetic Analysis at the Human NR2F2 Gene Locus
Discovery and genotyping in the DESIR cohort. In order
to assess part of the functional basis of NR2F2 in relation to
glucose homeostasis in humans, we have tested the hypothesis that
variations in the allelic distribution of common SNPs at the
NR2F2 locus impact glucose metabolism-related quantitative
traits. Three common SNPs (rs3743462, rs1807198 and rs11045,
with a minor allele frequency (MAF) .0.10), located in a 12.5-kbp
genomic interval at the NR2F2 locus on human chromosome
15q26, were analyzed as previously described [9]. We first
measured their association in a subset of 654 normoglycemic
non-obese individuals selected from the prospective DESIR cohort
[10]. Only one SNP, rs3743462, showed trends of association with
lower fasting insulin plasma concentrations, lower indices of basal
insulin secretion (HOMA-B) and insulin resistance (HOMA-IR)
(P#0.002). This gene variant is located in an upstream regulatory
region of the NR2F2 gene, at 23,138 bp from the transcription
start site (Fig. 2A) and the effect allele is characterized by the
substitution of a thymidine by a cytosine. No strong linkage
disequilibrium (LD) (r2,0.50 from the HapMap3 database) was
seen between rs3743462 and 14 other common SNPs present over
a 500 kbp region encompassing the NR2F2 locus.
The entire DESIR cohort, comprising 4,833 subjects of whom
3,877 were followed-up for 9 years [10], was genotyped for the
NR2F2-rs3743462 variant. The frequency of the minor C-allele of
rs3743462 was 14%. The association between NR2F2-rs3743462
and quantitative glucose homeostasis traits was evaluated in 3,341
non diabetic healthy individuals by using mixed regression models
with data adjusted for age, sex and body mass index (BMI). The
minor C-allele showed a significant negative association with
fasting insulin levels (P=0.005) and HOMA-IR index (P=0.0026)
(Table 1). When the regression was not adjusted for BMI, the
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Figure 1. Glucose decreases the ability of HNF4a to activate the transcription of the NR2F2 proximal promoter and to bind its
chromatin target. (A) INS-1 832/13 cells were transiently co-transfected as described in [7] with a luciferase reporter gene driven by various lengths
of the NR2F2 promoter, designated by their 59 and 39 end positions relative to the defined NR2F2 gene transcription initiation site [25] and a control
vector expressing Renilla luciferase. Cells were cultured in the presence of either 5 mM (white bars) or 20 mM (black bars) glucose. Results were
calculated from the ratio of luciferase/Renilla activity. Background expression was subtracted using the mean expression level of empty pGL3-basic.
Means6 SEM of results obtained from at least three independent transfections performed in triplicate are shown. *Significant differences, P,0.05. (B)
Comparison of mRNA levels of NR2F2 and HNF4a relative to those of cyclophilin determined by real-time RT-QPCR in INS-1 832/13 b-cells stimulated
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association was of greater significance for both insulin and
HOMA-IR (Table S1). No significant genotype correlation with
the fasting glucose concentrations or the basal b-cell insulin
secretion index (HOMA-B) was observed in the DESIR cohort
(Table 1); only a weak trend of association was observed for
HOMA-B when regression was not adjusted for BMI (Table S1).
No association of NR2F2-rs3743462 was observed with weight,
BMI or whole-body adiposity index (BAI) [11] in the DESIR
cohort. We also observed an association between rs3743462 C-
allele and height (P=0.0026). No association with the prevalence
or incidence of type 2 diabetes (T2D) was observed when we
included incident diabetic cases during follow-up and individuals
diabetic at entry into the study.
Follow-up Studies
We attempted to replicate these associations for fasting insulin,
HOMA-IR and height in the population-based NFBC-1966
(n = 3,476 individuals with one measurement point at age 31 for
all participants) (Table S2). Although we had a statistical power of
95% to detect the observed genetic effect size, no association was
observed for the tested traits (P.0.05) in this population of Finnish
ancestry. Similarly, no evidence of association was found in the
NFBC-1986 and the MAGIC meta-analysis dataset [12]. We
suspect these differences may be due to inter-cohort phenotypic
and genetic heterogeneity. For instance, we observed a MAF of
14%, 22% and 17%, in the DESIR, NFBC-1966 (and NFBC-
1986) and MAGIC studies, respectively.
Characterization and Functional Analysis of the NR2F2-
rs3743462 Variants in a Pancreatic b-cell line
The genetic variant rs3743462 is located in the distal promoter
of NR2F2, a sequence highly conserved across species (Fig. 2A).
We undertook a biochemical approach to assess whether allelic
variation at the rs3743462 polymorphism could affect NR2F2
promoter activity. We found this DNA region in a NR2F2/HRE
motif. NR2F2 is considered to be the most promiscuous nuclear
receptor that recognizes direct, inverted or palindromic repeats of
the HRE motif ‘‘A/GGGTCA’’ with different interspaced
distances [13,14]. Electrophoresis mobility shift assay (EMSA)
was used to investigate whether the protein NR2F2 binds to the
NR2F2 distal promoter region in vitro. 32P labeled double-stranded
oligonucleotides, rs3743462-T and rs3743462-C probes (Fig. 2B)
were incubated with INS-1 832/13 nuclear extracts. We identified
two DNA-protein complexes (Fig. 2C) with higher affinity for the
rs3743462-C oligonucleotide probe than the rs3743462-T
(Fig. 2C). Competition with non-labeled DNA at various
concentrations (Fig. 2D) further demonstrated that the
rs3743462-C oligonucleotide competed more efficiently than the
rs3743462-T oligonucleotide for the formation of DNA-protein
complexes. In fact, quantification of the results from several
experiments (data not shown) suggested that the protein binding
capacity of the rs3743462-C oligonucleotide was approximately
five-fold higher than for the rs3743462-T oligonucleotide. To
further establish that NR2F2 was involved in the DNA-protein
complexes, we then performed EMSA with nuclear extracts of
INS-1 832/13 cells, preincubated with antisera specific to NR2F2
or the upstream stimulatory factor (USF) used as a control [15]. As
shown in Fig. 2E, incubation with antibodies specific to NR2F2
resulted in a supershift in the migration of both complexes. A pre-
incubation with anti-USF had no effect (Fig. 2E). This result
strongly supported the fact that the DNA-protein complexes are
characterized by binding of NR2F2. Finally, together with the
previous observations showing a higher capacity of the variant
rs3743462-C oligonucleotide to create these complexes in
comparison to the rs3743462-T oligonucleotide in vitro (Fig. 2C
and Fig. 2D), this suggests that rs3743462-C has a greater affinity
to bind with NR2F2.
We next investigated the functional impact of altered NR2F2
binding on the NR2F2 promoter activity in b-cells cultured in
5 mM glucose, the condition that allows maximal expression of
NR2F2. We generated luciferase reporter plasmids controlled by
either the rs3743462-C or -T allele in the 23210/+873 NR2F2
promoter region. Figure 2F shows that the presence of the
rs3743462-C allele was associated with a 26% reduction in the
activity of the promoter in comparison to the rs3743462-T allele
(P,0.05). Finally, we mutated the DR-1/HNF4a binding site in
the construct with the rs3743462-C or -T alleles in the 23210/
+873 NR2F2 promoter region (Fig. 2F). The addition of the DR1
mutated DNA binding site to the rs3743462-C allele led to a lower
transcriptional activity. Nonetheless, the amplitude of changes in
luciferase activity between the two allele constructs was not
affected indicating that the rs3743462-C allele that binds NR2F2
does not require a functional DR1-HNF4a site in order to repress
transcription.
Discussion
Several recent studies on rodent models suggest that NR2F2 is
involved in glucose homeostasis and in energy metabolism
([1,3,4,5] and L. Sabra-Makke et al. in preparation). Interestingly,
NR2F2 is also regulated by nutrients and hormones [3,6]. For
instance, its expression is repressed directly in response to
exogenous insulin and indirectly in response to high glucose
concentrations through enhanced insulin secretion in pancreatic
b-cells [3].
In the present study, we showed that the proximal promoter of
NR2F2 is responsive to changes in glucose concentrations. In INS-
1 pancreatic b-cells, high glucose concentrations decreased both
the HNF4a-dependent ChIP signal on the DR-1 DNA binding
site and a DR-1-driven luciferase reporter gene transactivation.
These findings were further supported by the co-repression of
HNF4a and NR2F2 genes in the presence of 20 mM glucose
concentrations in INS-1 b-cells as previously described for HNF4a
expression in hepatocytes [16]. Altogether our data suggest that
the activation of NR2F2 gene expression in the fasted state, when
insulin and glucose concentrations are at their lowest, results in
part from the stimulation of HNF4a. Furthermore, we showed
with 5 mM (white bars) or 20 mM glucose (black bars) for 24 h as described in [3] (C) ChIP from INS-1 832/13 cells cultured in the presence of either
5 mM or 20 mM glucose. Targets for QPCR amplifications were the proximal NR2F2 promoter containing the DR1 DNA binding site or a downstream
coding region (negative control). Amount of target chromatin precipitated by the HNF4a-specific antibody relative to that precipitated by control IgG
(mean of three independent experiments 6 SEM). *Significant difference, P,0.05. (D) COS cells were transiently co-transfected with the 2328/+873
construct and 50 ng of empty KS vector (white bars), or HNF4a (grey bars) expression vectors. Means 6 SEM of results from at least three separate
transfections performed in triplicate are shown. *Significant difference, P,0.05. (E) INS-1 832/13 cells were transiently co-transfected with the wild-
type or mutated 2328/+873 constructs containing the DR1 elements. Cells were cultured in the presence of either 5 mM (white bars) or 20 mM
(black bars) glucose. Means 6 SEM of results from ten independent transfections performed in triplicate are shown. *Statistically significant
differences in percentage of expression (where value for 5 mM glucose is 100% relative to 2328/+873 construct) at P,0.05.
doi:10.1371/journal.pone.0035810.g001
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Figure 2. NR2F2 binds the variant rs3743462-C oligonucleotide with higher affinity than the rs3743462-T oligonucleotide and the
C-allele is associated with a strong decrease of NR2F2 gene expression relative to the T-allele. (A) Multiple alignments of the genomic
region between nucleotides 23180 and 23110 of the NR2F2 gene regulatory regions present in the 23210/+873 construct. Deletion is indicated by
dashes and points indicate identities. The sequence of the human complementary strand is shown above other sequences. Genomic sequences can
be retrieved from GenBank by their accession codes: Homo sapiens (NT_010274.17|:11836273-11840385), Mus musculus
(NT_039428.7|Mm7_39468_37:c10507606-10503510; reverse/complementary strand), Rattus norvegicus (NW_047560.2|Rn1_WGA2082_4:c5641306-
5636690; reverse/complementary strand). The position of the human SNP is indicated by an asteriskabove the sequences of each species: H. sapiens,
23,138; M. musculus, 23,139; R. norvegicus, 23,152 (where transcription start site is +1). (B) The sense strand sequences (+) of the oligonucleotides
used in EMSA are shown. SNP base pairs are shown in lower case letters. (C) The labeled rs3743462-T and rs3743462-C oligonucleotides were
incubated with INS-1 832/13 nuclear extracts, and protein binding was analyzed using EMSA. In the representative autoradiograph shown, only the
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that allelic variation at rs3743462 in a conserved cis-regulatory
region of the distal NR2F2 promoter is associated with fasting
insulin concentrations, the HOMA-IR index and adult height in
non diabetic individuals in the DESIR study. These three
phenotypic traits have previously been associated with metabolic
health in various populations [17]. The DESIR prospective cohort
is a comprehensively phenotyped general population of middle-
aged individuals, in which we previously analyzed several genetic
variants with confirmed significant effects either on T2D risk or on
glucose and lipid homeostasis quantitative traits [18,19,20,21]. By
assessing a genotype effect on continuous variables measured over
the 9-years of follow-up in the study, we are quite confident of the
validity of the associations between rs3743462 and the metabolic
variables tested in this large general population. However, our
follow-up study of these genetic associations in other European
populations did not replicate these observations. The latest meta-
analyses of fasting insulin and HOMA-IR from the MAGIC
consortium dataset did not show evidence of associations for
rs3743462 [12]. Furthermore, the GIANT meta-analysis of adult
BMI did not reveal any association at genome-wide level
significance between rs3743462 and adult BMI [22]. The allelic
change from T to C at the NR2F2-rs3743462 polymorphism
probably has modest effects on glucose homeostasis in vivo. Such
effects are very likely dependent on complex gene-environment
interactions that have yet to be disentangled. Nevertheless,
observation from the DESIR study, that variation within the
distal promoter region of NR2F2 is associated with whole-body
insulin sensitivity, is partly consistent with the phenotype of NR2F2
retarded complexes are visible and not the free probe, which was in excess. (D) Comparison of the affinity of protein binding to the rs3743462-T and
rs3743462-C variants. The labeled rs3743462-C oligonucleotide (Fig. 2B) was incubated with or without the indicated molar excess of unlabeled
rs3743462-T or rs3743462-C oligonucleotide as competitors before addition of INS-1 832/13 nuclear extract. Protein binding was then analyzed using
EMSA. In the representative autoradiograph shown, only the retarded complexes are visible and not the free probe, which was in excess. (E) INS-1
832/13 nuclear extracts were incubated with or without of the indicated anti-serum. The labeled oligonucleotide representing the 23153/23126
NR2F2 regulatory region and containing the rs3743462-C allele was added and protein binding was analyzed using EMSA. In the representative
autoradiograph shown, only the retarded complexes are visible and not the free probe, which was in excess. (F) Functional analysis of the rs3743462
alleles in pancreatic b-cells. INS-1 832/13 cells were transiently co-transfected using lipofectamine solution containing either rs3743462 T-allele, C-
allele, T-allele with DR-1 mutated site or C-allele with DR-1 mutated site within the context of the 3210/+873 sequences (1.5 mg) and expression
vector encoding Renilla luciferase (0.1mg). Cells were then cultured in the presence of 5 mM glucose for 14 h. Results are calculated from the ratio of
luciferase/Renilla activity. Means 6 SEM of results obtained from at least three independent transfections performed in triplicate are shown.
*Significant differences in expression at P,0.05.
doi:10.1371/journal.pone.0035810.g002
Table 1. Genotype correlation of NR2F2 rs3743462 polymorphism on glucose homeostasis parameters and height in the French
prospective DESIR cohort using up to four repeated measurements over the 9-year follow-up study.
Number of
observations P value* Effect size Overall mean 6 SD
b-coefficient (95% CI)* TT TC CC
Fasting plasma glucose (mmol/l)
additive 11,564 0.37 20.008 (20.026, 0.010) 5.3060.52 5.2860.53 5.2660.46
dominant 0.51 20.007 (20.027, 0.013)
recessive 0.28 20.035 (20.097, 0.028)
Fasting serum insulin (pmol/l)
additive 11,558 0.005 22.498 (24.199, 20.777) 50.68631.95 48.66634.18 48.21629.86
dominant 0.008 22.625 (24.524, 20.688)
recessive 0.10 25.010 (210.694, 1.035)
HOMA-IR
additive 11,530 0.003 22.849 (24.648, 21.005) 2.0061.38 1.9261.48 1.8461.15
dominant 0.006 22.878 (24.896, 20.817)
recessive 0.04 26.695 (212.672, 20.309)
HOMA-B
additive 11,520 0.10 21.538 (23.352, 0.3105) 102.71669.40 102.53696.80 97.23663.15
dominant 0.16 21.499 (23.526, 0.582)
recessive 0.19 24.247 (210.33, 2.255)
Height (cm)
additive 13,470 0.0026 0.316 (0.111, 0.522) 165.7669.10 165.9469.43 168.03 6 9.57
dominant 0.006 0.323 (0.094, 0.553)
recessive 0.052 0.723 (20.007, 1.452)
*The P values and b-coefficients are from the ‘‘mixed’’ regression model of each trait against genotype with age, gender and BMI as covariates (except for height
adjusted for age and gender). The P-values indicated are nominal P-values.
The b-coefficient denotes the effect of rs3743462 minor C-allele and genotypes (depending on the genetic model tested) on the traits analyzed, i.e. the increase or
decrease of the mean value for a specific trait.
doi:10.1371/journal.pone.0035810.t001
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heterozygous knockout mice [4] which show improved glucose
homeostasis and increased energy expenditure. These mutant
mice displayed normal fasted plasma glucose, lower fasted insulin
concentrations and improved insulin sensitivity.
Interestingly, we showed in a pancreatic b-cell line that the
presence of the rs3743462-C allele enhances NR2F2 binding to its
distal promoter. Our NR2F2 fusion gene assay with the C-allele of
the SNP resulted in a repression of gene activity compared to the
T allele suggesting that the binding of NR2F2 to its distal
promoter participates in decreasing NR2F2 expression. These
observations are consistent with previous experiments where over-
expression of NR2F2 decreased endogenous NR2F2 mRNA
abundance in pancreatic b-cells [7], suggesting a possible negative
feedback of NR2F2 on its own gene transcription. It would be
interesting to test NR2F2 binding in vivo but since it is the mutation
that promotes increased NR2F2 binding it is not easy to realize
these experiments.
We have shed light on the importance of both HNF4a and
NR2F2 itself in the control of its expression and suggested an
HNF4a-dependent site that contributes to regulate NR2F2
transcription in response to glucose concentrations changes. Our
data are suggestive of a greater affinity of NR2F2 to control its
own promoter in the presence of the rs3743462-C allele that is
associated with whole-body insulin sensitivity in a general
population of non diabetic individuals. The role of NR2F2
regulation in the aetiology of complex metabolic diseases, such as
the metabolic syndrome and T2D has yet to be fully understood.
In conclusion, our data suggest that NR2F2 might be a key factor
in novel strategies aiming to prevent or treat some of the metabolic
defects related to insulin resistance in humans.
Methods
Ethical Statements
All subjects included in the DESIR and NFBC 1966 studies
gave written consent, and the protocol was approved by the ethics
committee of Biceˆtre Hospital, Kremlin-Biceˆtre, France for
DESIR and the University Hospital of Oulu in accordance with
the declaration of Helsinki for NFBC 1966.
Study Cohorts
Participants in DESIR (Data from an Epidemiological Study on
the Insulin Resistance syndrome), a prospective study of a middle-
aged French cohort fully described elsewhere [10], were clinically
and biologically evaluated at inclusion and at 3-year, 6-year and 9-
year follow-up visits [18]. Of the 4,833 individuals of European
ancestry included, 3,877 were examined at each 3-year follow-up
visit over the entire 9-year study. This number includes 3,570 non
diabetic individuals who did not receive treatment with hypogly-
cemic drugs over the period of the study. All subjects included in
the study gave their informed consent, and the protocol was
approved by the ethics committee of Biceˆtre Hospital, Kremlin-
Biceˆtre, France.
The population-based cohort Northern Finland Birth Cohort
(NFBC)-1966 is a genetically homogeneous birth cohort of white
Caucasians born in the two northernmost provinces of Finland
(Oulu and Lapland). It consists of an unselected population of
white Caucasian mothers and their offspring with expected dates
of delivery from between end of 1965 and early in 1967 [23].
Extensive growth measurements and clinical examinations of the
offspring were conducted from birth until age 31. At age 31, fasted
blood samples were withdrawn from the offspring for metabolic
profiling and genotyping. The present study included the data of
singleton term-born offspring. All individuals included in the
present study (n= 3,476; male-to-female ratio = 1) were normo-
glycemic (fasted glycemia #5.6 mmol/l) with normal BMI
(#25 kg/m2 for all participants). All participants and their parents
gave written informed consent. The study protocol has been
approved by the ethics committee of the Faculty of Medicine of
the University of Oulu and the Finland Ministry for Social and
Health Affairs.
SNP Genotyping
Genotyping of rs3743462 in the DESIR cohort was performed
using TaqMan Technology (assay nuC-395241-10, Applied
Biosystems, Foster City, CA, USA). A genotyping success rate of
98.8% was achieved in samples from the whole cohort. Duplicate
samples were assayed with a concordance rate of 100%. The
genotype distribution of rs3743462 was in Hardy-Weinberg
equilibrium (p.0.20). The genotype data for rs3743462 in the
NFBC-1966 cohort were available from a previously published
genome-wide study [24].
Genetic and Statistical Analyses
In the DESIR cohort, the correlation between rs3743462
genotypes and quantitative parameters was assessed using data
from untreated individuals both at inclusion and 3, 6 and 9 years
later [18]. The normoglycemic status was defined as a fasting
plasma glucose (FPG) of ,6.1 mmol/l in the absence of
hypoglycemic treatment (according to 1997 American Diabetes
Association criteria). In the NFBC-1966 cohort, the effect of
rs3743462 was tested on the measurements at age 31 years in all
included participants.
The quantitative trait data were log-transformed before analysis
(when required) and adjusted for age and sex, and BMI when
specified. We used linear regression models for analyses of one
measurement point and mixed regression models for analyses of
follow-up data [18] with adjustment for co-variables (age and/or
sex and BMI). All analyses were performed using R (Rproject.org).
Plasmids and Site-directed Mutagenesis
In the following description, in construct names and throughout
the paper, when referring to NR2F2 gene structure, numbers
designate the position of nucleotides relative to the known
transcription initiation site at +1 [25]. The mouse and human
regulatory regions studied are nearly identical (see Figure 2A). The
reporter plasmids 2328/+873 and 248/+873 (corresponding to
2328/luc and 248/luc respectively) and 2328 mutated DR-1
site/+873 (2328M/luc) have been previously described [7]. The
reporter plasmids 23210/+873 (T-allele at rs3743462) and
23210/+873 (C-allele at rs3743462) were obtained by cloning
a synthesized 493-bp mouse COUP-TFII fragment between the
KpnI (23210) and PvuII (22717) sites (GENEART AG,
Regensburg) into the 23000/+873 plasmid (23000/luc), de-
scribed in [7], digested with KpnI and PvuII. Site-directed
mutagenesis of the reporter plasmids 23210/+873 (T- and C-
alleles at rs3743462) in the DR-1 site was performed by GeneCust,
Europe). All new constructs were completely sequenced. The
Renilla luciferase plasmid, the pcDNA plasmid encoding HNF4a
has been previously described [7].
Cell Culture, Transfection and Reporter Gene Assay
Transfection and reporter gene assays were done as previously
described [7]. Rat pancreatic INS-1 832/13 cells generously
provided by C. Newgard (6106/well) [7] or COS-7 fibroblast cells
(Invitrogen) were transiently transfected, using lipofectamine 2000
reagent (Invitrogen), with the luciferase reporter gene downstream
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of different portions of the mouse NR2F2 promoter (0.45 mg of
DNA) and a control vector expressing Renilla luciferase (0.1 mg of
DNA). Transfected cells were cultured in 5 mM or 20 mM
glucose as described [3] and harvested 14 h after transfection.
Where necessary, transcriptional efficiency was first determined by
transfecting different amounts of the reporter constructs; 1.5 mg of
DNA and 0.1 mg of control vector expressing Renilla were optimal
for obtaining significantly different activities between constructs.
Cell extracts were assayed for reporter enzyme activities using the
Dual-Luciferase Reporter Assay System kit (Promega). Results
were calculated as the ratio of luciferase/Renilla. Background
expression, defined as the mean relative expression level of the
empty pGL3-basic construct, was subtracted from all other values.
The means 6 standard errors of the mean (SEM) represent data
from five to ten independent transfections performed in triplicate.
Nuclear Extract Preparation and EMSA
Nuclear extracts from 832/13 INS-1 cells were prepared as
described [7]. Electrophoresis mobility shift assays (EMSA), probe
labeling, binding reactions, antibody supershift analyses were
performed as reported previously [7]. Protein binding was
quantified by using Typhoon (GE Healthcare) to count the
proportion of 32P present in retarded complexes.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed
as previously described [26] with a slight modification of the
Upstate Biotechnology (Millipore) ChIP Assay Kit protocol
(catalog no. 17–295). Cells were treated for 16 h in 5 mM glucose
prior to a 6-h treatment with 20 mM glucose. Extracted
chromatin was sonicated using a Diagenode Bioruptor (Liege,
Belgium) for 15 min. Antibodies from Santa Cruz Biotechnology
used in ChIP experiments were HNF4a (H-171) (catalog no. sc-
8987) and IgG (catalog no. sc-2027). Sequences of the primers
used are: 59-TGAACTTTGACACGACTGCTG-39 and 59-
GCTAGGACCGGGCTGTTC-39 for the COUP-TFII promot-
er; and 59-CAGCAGCAGCACATCGAG-39 and 59-GGCAG-
TACTGGCACTGGTTG-39 for the COUP-TFII coding region.
Statistical Analysis
Quantitative results are expressed as means 6 SEM. Statistical
analyses were carried out using the Mann-Whitney test, a non-
parametric statistical test appropriate when the sample number is
less than 10. Null hypotheses were rejected at P values of .0.05.
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